Health Canada Allows COVID-19 Patients with Respiratory Failure to Be Given NuvOx Pharma’s Oxygen Therapeutic in Phase IIa Clinical Trial

Editorial & Advertiser Disclosure Global Banking And Finance Review is an independent publisher which offers News, information, Analysis, Opinion, Press Releases, Reviews, Research reports covering various economies, industries, products, services and companies. The content available on globalbankingandfinance.com is sourced by a mixture of different methods which is not limited to content produced and supplied by various staff writers, journalists, freelancers, individuals, organizations, companies, PR agencies Sponsored Posts etc. The information available on this website is purely for educational and informational purposes only. We cannot guarantee the accuracy or applicability of any of the information provided at globalbankingandfinance.com with respect to your individual or personal circumstances. Please seek professional advice from a qualified professional before making any financial decisions. Globalbankingandfinance.com also links to various third party websites and we cannot guarantee the accuracy or applicability of the information provided by third party websites. Links from various articles on our site to third party websites are a mixture of non-sponsored links and sponsored links. Only a very small fraction of the links which point to external websites are affiliate links. Some of the links which you may click on our website may link to various products and services from our partners who may compensate us if you buy a service or product or fill a form or install an app. This will not incur additional cost to you. A very few articles on our website are sponsored posts or paid advertorials. These are marked as sponsored posts at the bottom of each post. For avoidance of any doubts and to make it easier for you to differentiate sponsored or non-sponsored articles or links, you may consider all articles on our site or all links to external websites as sponsored . Please note that some of the services or products which we talk about carry a high level of risk and may not be suitable for everyone. These may be complex services or products and we request the readers to consider this purely from an educational standpoint. The information provided on this website is general in nature. Global Banking & Finance Review expressly disclaims any liability without any limitation which may arise directly or indirectly from the use of such information.

NuvOx Pharma, a Tucson-based biotechnology company developing NanO2„¢ emulsion for oxygen delivery, has received a No Objection Letter from Health Canada to proceed with a Phase IIa clinical trial of NanO2 in COVID-19 subjects with acute hypoxic respiratory failure (AHRF). Some patients with AHRF can progress to a more severe form of the disease called acute respiratory distress syndrome (ARDS). ARDS, which is associated with lung inflammation leading to low blood oxygenation, is the major cause of death in COVID-19 patients. Evan Unger, MD, President and CEO of NuvOx Pharma, said, We had data in several animal models showing that NanO2 restored oxygen levels in conditions of low oxygen caused by ARDS or acute lung injury. We already have data in humans from when NanO2 was tested in subjects with brain cancer and stroke showing safety and evidence of efficacy in both indications. Because of this, we designed a clinical trial to study NanO2 in COVID-19 patients.

Diego Martin, MD, PhD, Chairman of Radiology at McGill University, Montreal, Canada, Principal Investigator of the Canadian efforts on the trial, said, We are excited to collaborate with NuvOx Pharma on this project. I have been collaborating with Dr. Unger to study models of myocardial infarction where we have published evidence that shows NanO2 can act as a cardioprotectant. In addition to ARDS, COVID-19 patients suffer multi-organ damage to the heart, brain, kidneys and other organs. In fact, a large percentage of patients who succumb to COVID-19 also have underlying cardiac disease or cardiovascular risk factors. NanO2 appears to be reversing ischemia-mediated pathways of inflammation and tissue injury in lung, heart and other tissues, which may make it particularly well-suited as a treatment in COVID-19 subjects.

Jarrod Mosier, MD, Associate Professor with Tenure Emergency & Internal Medicine and Associate Program Director of the Critical Care Fellowship at Banner University Medical Center, Tucson, AZ, is a Principal Investigator of the US sites in the clinical trial. Dr. Mosier said, NanO2 will be administered as a sustained IV infusion in the clinical trial. The first phase of the trial is a dose escalation design to determine the best dose, after which additional subjects will be enrolled at that dose as a dose expansion phase. The trial will determine if NanO2 improves clinical outcomes in COVID-19 subjects with acute hypoxic respiratory failure. NanO2 has the potential to transform the care of COVID-19 patients who present with low oxygen saturation.

Disclaimer: Certain statements in this release may constitute forward-looking statements. Actual events or results may differ substantially as a result of risks and uncertainties facing us. The forward-looking statements are based on current expectations as of the date of these statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of future events, new information, or otherwise.

John McGonigle

[email protected]